This Research Topic is part of a series with:
Neuroinflammatory and Oxidative/Nitrosative Pathways in Neuropsychiatric and Neurological Diseases and Their Possible Neuropharmacological Regulation, Volume INeurological and neuropsychiatric diseases are rising as leading causes of death, disability, and disease burden. However, the pathophysiology of many of these disorders remains elusive and more importantly, a large percentage of patients fail to achieve remission despite multiple treatment trials. Consequently, there is a pressing need to identify novel pathophysiological pathways relevant to these diseases, uncovering new therapeutic targets, and finding related biomarkers for the identification and monitoring of potentially responsive patients. One promising development in this regard is the emergence of the immune system and the neuroinflammatory and oxidative/nitrosative stress responses as parameters playing a role in neuropsychiatric and neurological diseases. Targeting the neuroinflammation and/or the oxidative/nitrosative stress could provide new therapeutic possibilities, opening the opportunity to translational studies in neurological and neuropsychiatric pathologies.
Considering the potential part of neuroinflammation and the subsequent oxidative/nitrosative damage in the pathophysiology of the neurological and neuropsychiatric diseases, the characterization of potential pharmacological targets as well as the study of the molecular mechanisms involved are necessary. The better understanding of the neuroinflammatory signaling and the oxidative/nitrosative processes might uncover new methodologies to settle down exacerbated neuroinflammatory states and in the long term could reveal novel pharmacological targets. Thus, bearing in mind the potential role previously mentioned, the development of new drugs based in the immune response mechanisms is a necessary approach for future therapeutic interventions that deserves further consideration from the standpoint of the neuropharmacology. The neuroinflammation is a subject matter rapidly evolving, and thus, the goal of this Research Topic is to offer a view of the current developments in the neuroimmune pharmacology realm for the neurological and neuropsychiatric diseases.
This Research Topic will include studies addressing the role of neuroinflammatory and/or oxidative/nitrosative pathways and their possible neuropharmacological regulation and will especially welcome clinical or experimental Original Research and Review articles. Some proposed themes are:
• The role of the innate immune system in experimental models and its possible neuropharmacological regulation.
• The role of the oxidative/nitrosative stress in experimental models and its possible neuropharmacological regulation.
• The role of the innate immune system and of the oxidative/nitrosative stress in patients.
• Neuropharmacological actions of current and new drugs affecting the neuroinflammation and/or the oxidative/nitrosative stress in experimental models or in patients.
• Characterization of neuroinflammatory and oxidative/nitrosative pathways being affected in experimental models and/or patients.
• Identification of potential new neuroinflammation-related therapeutic targets and/or biomarkers.
This Research Topic is part of a series with:
Neuroinflammatory and Oxidative/Nitrosative Pathways in Neuropsychiatric and Neurological Diseases and Their Possible Neuropharmacological Regulation, Volume INeurological and neuropsychiatric diseases are rising as leading causes of death, disability, and disease burden. However, the pathophysiology of many of these disorders remains elusive and more importantly, a large percentage of patients fail to achieve remission despite multiple treatment trials. Consequently, there is a pressing need to identify novel pathophysiological pathways relevant to these diseases, uncovering new therapeutic targets, and finding related biomarkers for the identification and monitoring of potentially responsive patients. One promising development in this regard is the emergence of the immune system and the neuroinflammatory and oxidative/nitrosative stress responses as parameters playing a role in neuropsychiatric and neurological diseases. Targeting the neuroinflammation and/or the oxidative/nitrosative stress could provide new therapeutic possibilities, opening the opportunity to translational studies in neurological and neuropsychiatric pathologies.
Considering the potential part of neuroinflammation and the subsequent oxidative/nitrosative damage in the pathophysiology of the neurological and neuropsychiatric diseases, the characterization of potential pharmacological targets as well as the study of the molecular mechanisms involved are necessary. The better understanding of the neuroinflammatory signaling and the oxidative/nitrosative processes might uncover new methodologies to settle down exacerbated neuroinflammatory states and in the long term could reveal novel pharmacological targets. Thus, bearing in mind the potential role previously mentioned, the development of new drugs based in the immune response mechanisms is a necessary approach for future therapeutic interventions that deserves further consideration from the standpoint of the neuropharmacology. The neuroinflammation is a subject matter rapidly evolving, and thus, the goal of this Research Topic is to offer a view of the current developments in the neuroimmune pharmacology realm for the neurological and neuropsychiatric diseases.
This Research Topic will include studies addressing the role of neuroinflammatory and/or oxidative/nitrosative pathways and their possible neuropharmacological regulation and will especially welcome clinical or experimental Original Research and Review articles. Some proposed themes are:
• The role of the innate immune system in experimental models and its possible neuropharmacological regulation.
• The role of the oxidative/nitrosative stress in experimental models and its possible neuropharmacological regulation.
• The role of the innate immune system and of the oxidative/nitrosative stress in patients.
• Neuropharmacological actions of current and new drugs affecting the neuroinflammation and/or the oxidative/nitrosative stress in experimental models or in patients.
• Characterization of neuroinflammatory and oxidative/nitrosative pathways being affected in experimental models and/or patients.
• Identification of potential new neuroinflammation-related therapeutic targets and/or biomarkers.
